SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced ...

Sonnet BioTherapeutics (SONN) announced an expansion of its Phase 1 SB101 clinical study of SON-1010 in adult patients with advanced solid ...

While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer ...

The Arkansas Integrative Metabolic Research Center will host Jeffrey Rathmell, a professor of pathology, microbiology and immunology from Vanderbilt University on Wednesday, Jan. 22.

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...

Recurrent respiratory papillomatosis (RRP) is a disease of the upper airway presenting with exophytic wart-like lesions. These lesions are considered benign with less than a 1–5% chance of malignant ...

PRINCETON, NJ - Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage biotech company with a market capitalization of $4.63 million, has expanded its Phase 1 SB101 clinical trial to ...